Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.31
ELGX's Cash-to-Debt is ranked lower than
75% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. ELGX: 0.31 )
Ranked among companies with meaningful Cash-to-Debt only.
ELGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: No Debt Max: No Debt
Current: 0.31
Equity-to-Asset 0.22
ELGX's Equity-to-Asset is ranked lower than
91% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ELGX: 0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
ELGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.84 Max: 0.96
Current: 0.22
0.22
0.96
Debt-to-Equity 2.79
ELGX's Debt-to-Equity is ranked lower than
96% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.35 vs. ELGX: 2.79 )
Ranked among companies with meaningful Debt-to-Equity only.
ELGX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.25 Max: 2.79
Current: 2.79
0
2.79
Debt-to-EBITDA -5.08
ELGX's Debt-to-EBITDA is ranked lower than
99.99% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ELGX: -5.08 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ELGX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.08  Med: -1.37 Max: 0.31
Current: -5.08
-5.08
0.31
Piotroski F-Score: 4
Altman Z-Score: -0.64
Beneish M-Score: -2.94
WACC vs ROIC
5.21%
-22.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -29.86
ELGX's Operating Margin % is ranked lower than
79% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. ELGX: -29.86 )
Ranked among companies with meaningful Operating Margin % only.
ELGX' s Operating Margin % Range Over the Past 10 Years
Min: -58.38  Med: -21.37 Max: -4.47
Current: -29.86
-58.38
-4.47
Net Margin % -41.60
ELGX's Net Margin % is ranked lower than
79% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. ELGX: -41.60 )
Ranked among companies with meaningful Net Margin % only.
ELGX' s Net Margin % Range Over the Past 10 Years
Min: -80.17  Med: -32.34 Max: 15.84
Current: -41.6
-80.17
15.84
ROE % -73.43
ELGX's ROE % is ranked lower than
88% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. ELGX: -73.43 )
Ranked among companies with meaningful ROE % only.
ELGX' s ROE % Range Over the Past 10 Years
Min: -143.15  Med: -35.43 Max: 15.58
Current: -73.43
-143.15
15.58
ROA % -20.59
ELGX's ROA % is ranked lower than
78% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. ELGX: -20.59 )
Ranked among companies with meaningful ROA % only.
ELGX' s ROA % Range Over the Past 10 Years
Min: -44.79  Med: -19.56 Max: 11.48
Current: -20.59
-44.79
11.48
ROC (Joel Greenblatt) % -92.35
ELGX's ROC (Joel Greenblatt) % is ranked lower than
79% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. ELGX: -92.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ELGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -298.49  Med: -106.31 Max: -21.18
Current: -92.35
-298.49
-21.18
3-Year Revenue Growth Rate 4.10
ELGX's 3-Year Revenue Growth Rate is ranked higher than
51% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. ELGX: 4.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ELGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.3  Med: 11.85 Max: 68.4
Current: 4.1
-41.3
68.4
3-Year EBITDA Growth Rate 95.30
ELGX's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ELGX: 95.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ELGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.1  Med: -0.9 Max: 95.3
Current: 95.3
-51.1
95.3
3-Year EPS without NRI Growth Rate 94.40
ELGX's 3-Year EPS without NRI Growth Rate is ranked higher than
97% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. ELGX: 94.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ELGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.6  Med: 5.9 Max: 128.9
Current: 94.4
-51.6
128.9
GuruFocus has detected 3 Warning Signs with Endologix Inc ELGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELGX's 30-Y Financials

Financials (Next Earnings Date: 2018-02-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ELGX Guru Trades in Q4 2016

Steven Cohen 3,500 sh (New)
Columbia Wanger 6,317,747 sh (+462.99%)
Jim Simons 344,522 sh (+19.33%)
Pioneer Investments 632,999 sh (-34.26%)
» More
Q1 2017

ELGX Guru Trades in Q1 2017

Steven Cohen 622,400 sh (+17682.86%)
Jim Simons 503,891 sh (+46.26%)
Pioneer Investments 630,314 sh (-0.42%)
Columbia Wanger 6,026,829 sh (-4.60%)
» More
Q2 2017

ELGX Guru Trades in Q2 2017

Steven Cohen Sold Out
Pioneer Investments Sold Out
Jim Simons Sold Out
Columbia Wanger 5,244,360 sh (-12.98%)
» More
Q3 2017

ELGX Guru Trades in Q3 2017

Columbia Wanger 1,989,037 sh (-62.07%)
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:XKRX:039840, XSWX:CLTN, NAS:ENTL, XKRX:145720, HKSE:00801, XSWX:VBSN, SZSE:300573, TSE:4218, TSE:7749, SHSE:603880, NAS:PLSE, OSTO:ALIF B, MIL:SFL, BOM:531768, SZSE:300453, AMEX:TRXC, XKRX:119610, SZSE:300030, XKRX:041830, NAS:STAA » details
Traded in other countries:RM1.Germany,
Headquarter Location:USA
Endologix Inc develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. Its products are intended for the treatment of abdominal aortic aneurysms.

Endologix Inc develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. Its products are intended for the treatment of abdominal aortic aneurysms.

Top Ranked Articles about Endologix Inc

ENDOLOGIX ALERT: J&W Investigates Endologix, Inc.; Long Term Investors Encouraged to Contact the Firm
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Endologix, Inc. - ELGX
Columbia Wanger Buys LCI Industries, Nasdaq Largest buys by the firm in the 4th quarter
Columbia Wanger (Trades, Portfolio) manages a portfolio composed of 197 stocks with a total value of $7.123 billion. During the fourth quarter the guru bought shares in the following stocks: Read more...
EGLX UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endologix, Inc. and a Lead Plaintiff Deadline of March 6, 2017

NEW YORK, March 03, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Endologix, Inc. (NASDAQ:ELGX) securities between August 2, 2016 and November 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/endologix-inc. There is no cost or obligation to you. According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors. If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endologix-inc. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endologix Inc. (ELGX) and Lead Plaintiff Deadline: March 6, 2017

NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endologix Inc. (“Endologix” or the “Company”) (NASDAQ:ELGX) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Endologix securities August 2, 2016 through November 16, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/elgx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the necessary clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) consequently, the Company’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix revealed that the FDA requested the Company to provide them with follow up data for two years for patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/elgx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.10
ELGX's PB Ratio is ranked lower than
58% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. ELGX: 5.10 )
Ranked among companies with meaningful PB Ratio only.
ELGX' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 6 Max: 14.18
Current: 5.1
1.69
14.18
PS Ratio 2.38
ELGX's PS Ratio is ranked higher than
64% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. ELGX: 2.38 )
Ranked among companies with meaningful PS Ratio only.
ELGX' s PS Ratio Range Over the Past 10 Years
Min: 1.14  Med: 5.43 Max: 12.72
Current: 2.38
1.14
12.72
EV-to-EBIT -10.66
ELGX's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. ELGX: -10.66 )
Ranked among companies with meaningful EV-to-EBIT only.
ELGX' s EV-to-EBIT Range Over the Past 10 Years
Min: -194.1  Med: -20.6 Max: 6307.9
Current: -10.66
-194.1
6307.9
EV-to-EBITDA -12.78
ELGX's EV-to-EBITDA is ranked lower than
99.99% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. ELGX: -12.78 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -555.6  Med: -13.7 Max: 466.4
Current: -12.78
-555.6
466.4
EV-to-Revenue 3.27
ELGX's EV-to-Revenue is ranked higher than
59% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ELGX: 3.27 )
Ranked among companies with meaningful EV-to-Revenue only.
ELGX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 5.8 Max: 12.2
Current: 3.27
1.1
12.2
Current Ratio 2.90
ELGX's Current Ratio is ranked higher than
54% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. ELGX: 2.90 )
Ranked among companies with meaningful Current Ratio only.
ELGX' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 5.73 Max: 20.25
Current: 2.9
2.15
20.25
Quick Ratio 2.11
ELGX's Quick Ratio is ranked higher than
59% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. ELGX: 2.11 )
Ranked among companies with meaningful Quick Ratio only.
ELGX' s Quick Ratio Range Over the Past 10 Years
Min: 1.74  Med: 4.54 Max: 19.04
Current: 2.11
1.74
19.04
Days Inventory 239.08
ELGX's Days Inventory is ranked lower than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. ELGX: 239.08 )
Ranked among companies with meaningful Days Inventory only.
ELGX' s Days Inventory Range Over the Past 10 Years
Min: 168.66  Med: 215.97 Max: 301.48
Current: 239.08
168.66
301.48
Days Sales Outstanding 67.18
ELGX's Days Sales Outstanding is ranked lower than
57% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. ELGX: 67.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.06  Med: 65.71 Max: 77.86
Current: 67.18
58.06
77.86
Days Payable 60.91
ELGX's Days Payable is ranked higher than
57% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. ELGX: 60.91 )
Ranked among companies with meaningful Days Payable only.
ELGX' s Days Payable Range Over the Past 10 Years
Min: 60.91  Med: 109.95 Max: 189.92
Current: 60.91
60.91
189.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
ELGX's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. ELGX: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.1  Med: -9.85 Max: -2.8
Current: -9
-35.1
-2.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.43
ELGX's Price-to-Median-PS-Value is ranked higher than
93% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ELGX: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ELGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 1.23 Max: 9.38
Current: 0.43
0.25
9.38
Earnings Yield (Greenblatt) % -9.40
ELGX's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ELGX: -9.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ELGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -29.9  Med: -4.8 Max: -0.5
Current: -9.4
-29.9
-0.5

More Statistics

Revenue (TTM) (Mil) $184.62
EPS (TTM) $ -0.93
Beta0.26
Short Percentage of Float17.51%
52-Week Range $4.08 - 7.91
Shares Outstanding (Mil)83.45

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 182 190
EPS ($) -0.64 -0.51
EPS without NRI ($) -0.64 -0.51
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}